Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-07

AUTHORS

Andrew C. Tiu, Rashmika Potdar, Djeneba Audrey Djibo, Muhammad Masab, Claudia Dourado

ABSTRACT

African Americans (AA) have the highest incidence and mortality rates with lung cancer. They are diagnosed at an earlier age with more advanced disease. Programmed cell death protein-1 inhibitor, Nivolumab, was approved as a second-line agent after failure of platinum-based therapy for advanced or metastatic non-small cell lung cancer (NSCLC). The original studies leading to the approval of Nivolumab had insufficient AA patients, thus there is still inadequate knowledge on treatment outcomes among AA patients. Our primary study endpoints were to determine the median overall survival, 1-year overall survival rate, median progression-free survival, and 1-year progression-free survival rate of patients with advanced or metastatic non-small cell lung cancer on Nivolumab. Our secondary study endpoints were to determine the overall tumor response rate, median time to response, median duration of response, and incidence of treatment-related adverse events of grade 3 or 4. In this retrospective study, we reviewed the charts of 38 patients, 29 of which were AA, with advanced or metastatic NSCLC who received Nivolumab from March 1, 2015 until November 30, 2017 from a single community-based cancer center and compared our results with historical data. Adenocarcinoma was the most common histology (71%) among all patients. Seven (18%) continued to use Nivolumab while 21 (55%) discontinued the treatment mainly due to progression of the disease. The median overall survival was 21.4 months (95% CI 13.5-27.4) and 17.6 months (95% CI 11.5-27.6) for all the patients and AA, respectively. Both have statistically significant difference (P < 0.001) compared to the historical studies of Borghaei et al. and Brahmer et al. At 1 year, the overall survival rate was 73% (95% CI 50-86) and 66% (95% CI 40-82) for all patients and AA, respectively. The median progression-free survival was also statistically significant (P < 0.001) between all the patients 6.3 months (95% CI 2.8-8), AA 6.0 months (95% CI 2.3-8.0), and the said historical studies. The 1-year progression-free survival rate was 23% (95% CI 10-39) and 28% (95% CI 12-47) for all patients and AA, respectively. Overall tumor response rate which includes complete and partial responses was 21% (95% CI 10-37) and 24% (95% CI 10-43) for all patients and AA, respectively. The median time to response was 3 and 2.8 months for all patients and AA, respectively. The median duration of response was 3.8 and 4.0 months for all patients and AA, respectively. Treatment-related adverse events of grade 3 or 4 were reported in 8 and 10% in all patients and AA, respectively, similar to the rates previously shown. AA patients with advanced or metastatic NSCLC on Nivolumab had increased overall survival and progression-free survival with similar grade 3 or 4 treatment-related adverse events. Providing adequate access to immunotherapy is indispensable to maximize survival benefit for AA patients. More... »

PAGES

109

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12032-018-1171-y

DOI

http://dx.doi.org/10.1007/s12032-018-1171-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104908927

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29915891


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "African Americans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Non-Small-Cell Lung", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Community Health Centers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Albert Einstein Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.239276.b", 
          "name": [
            "Department of Medicine, Einstein Medical Center, 5501 Old York Road, 19141, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tiu", 
        "givenName": "Andrew C.", 
        "id": "sg:person.016702546124.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016702546124.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Albert Einstein Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.239276.b", 
          "name": [
            "Division of Hematology and Medical Oncology, Einstein Medical Center, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Potdar", 
        "givenName": "Rashmika", 
        "id": "sg:person.010270370327.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010270370327.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Albert Einstein Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.239276.b", 
          "name": [
            "Department of Medicine, Einstein Medical Center, 5501 Old York Road, 19141, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Djibo", 
        "givenName": "Djeneba Audrey", 
        "id": "sg:person.01362157656.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362157656.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Albert Einstein Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.239276.b", 
          "name": [
            "Department of Medicine, Einstein Medical Center, 5501 Old York Road, 19141, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masab", 
        "givenName": "Muhammad", 
        "id": "sg:person.0761661517.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761661517.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Albert Einstein Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.239276.b", 
          "name": [
            "Division of Hematology and Medical Oncology, Einstein Medical Center, Philadelphia, PA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dourado", 
        "givenName": "Claudia", 
        "id": "sg:person.016130301335.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016130301335.85"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1507643", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000663586"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21340", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002091226"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2016.2453", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004154633"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2013.05.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013015846"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmc1514790", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013879074"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21387", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014894112"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/2193-1801-3-710", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023434538", 
          "https://doi.org/10.1186/2193-1801-3-710"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2015-0507", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026363244"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mds023", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031642811"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.canep.2015.10.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034640872"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2010.545", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038051303", 
          "https://doi.org/10.1038/onc.2010.545"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cam4.348", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045531700"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.29812", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046490428"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.29812", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046490428"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0b013e3182762ce4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048177896"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/ca.2007.0011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050648457"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0000000000000687", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051740635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1504627", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052572745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cllc.2017.02.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083906247"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30074-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084052467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2016-0419", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084355313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ijrobp.2017.01.178", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084739783"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.chest.2017.04.177", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085384884"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1613493", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086112913"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1613493", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086112913"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.2017-0133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1086386152"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/esmoopen-2017-000236", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091409434"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2017.2925", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092066753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jtho.2017.09.945", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092571697"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.lungcan.2017.11.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092855159"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-17-0527", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1093088390"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.21037/tlcr.2017.12.10", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099894161"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.21873/anticanres.12466", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101851958"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758835918763493", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103149559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758835918763493", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103149559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758835918763493", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103149559"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1801946", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103285297"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-07", 
    "datePublishedReg": "2018-07-01", 
    "description": "African Americans (AA) have the highest incidence and mortality rates with lung cancer. They are diagnosed at an earlier age with more advanced disease. Programmed cell death protein-1 inhibitor, Nivolumab, was approved as a second-line agent after failure of platinum-based therapy for advanced or metastatic non-small cell lung cancer (NSCLC). The original studies leading to the approval of Nivolumab had insufficient AA patients, thus there is still inadequate knowledge on treatment outcomes among AA patients. Our primary study endpoints were to determine the median overall survival, 1-year overall survival rate, median progression-free survival, and 1-year progression-free survival rate of patients with advanced or metastatic non-small cell lung cancer on Nivolumab. Our secondary study endpoints were to determine the overall tumor response rate, median time to response, median duration of response, and incidence of treatment-related adverse events of grade 3 or 4. In this retrospective study, we reviewed the charts of 38 patients, 29 of which were AA, with advanced or metastatic NSCLC who received Nivolumab from March 1, 2015 until November 30, 2017 from a single community-based cancer center and compared our results with historical data. Adenocarcinoma was the most common histology (71%) among all patients. Seven (18%) continued to use Nivolumab while 21 (55%) discontinued the treatment mainly due to progression of the disease. The median overall survival was 21.4\u00a0months (95% CI 13.5-27.4) and 17.6\u00a0months (95% CI 11.5-27.6) for all the patients and AA, respectively. Both have statistically significant difference (P\u2009<\u20090.001) compared to the historical studies of Borghaei et al. and Brahmer et al. At 1 year, the overall survival rate was 73% (95% CI 50-86) and 66% (95% CI 40-82) for all patients and AA, respectively. The median progression-free survival was also statistically significant (P\u2009<\u20090.001) between all the patients 6.3\u00a0months (95% CI 2.8-8), AA 6.0\u00a0months (95% CI 2.3-8.0), and the said historical studies. The 1-year progression-free survival rate was 23% (95% CI 10-39) and 28% (95% CI 12-47) for all patients and AA, respectively. Overall tumor response rate which includes complete and partial responses was 21% (95% CI 10-37) and 24% (95% CI 10-43) for all patients and AA, respectively. The median time to response was 3 and 2.8\u00a0months for all patients and AA, respectively. The median duration of response was 3.8 and 4.0\u00a0months for all patients and AA, respectively. Treatment-related adverse events of grade 3 or 4 were reported in 8 and 10% in all patients and AA, respectively, similar to the rates previously shown. AA patients with advanced or metastatic NSCLC on Nivolumab had increased overall survival and progression-free survival with similar grade 3 or 4 treatment-related adverse events. Providing adequate access to immunotherapy is indispensable to maximize survival benefit for AA patients.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12032-018-1171-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094524", 
        "issn": [
          "1357-0560", 
          "1559-131X"
        ], 
        "name": "Medical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "name": "Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center", 
    "pagination": "109", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "e40e235f1b0f3597216ba58675df465f8e2bb9d294e117753c86ade66ba71f15"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29915891"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9435512"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12032-018-1171-y"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104908927"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12032-018-1171-y", 
      "https://app.dimensions.ai/details/publication/pub.1104908927"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T20:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8681_00000565.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs12032-018-1171-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12032-018-1171-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12032-018-1171-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12032-018-1171-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12032-018-1171-y'


 

This table displays all metadata directly associated to this object as RDF triples.

262 TRIPLES      21 PREDICATES      78 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12032-018-1171-y schema:about N064a95a29fc442b0888e2b47df827d91
2 N0a1e0b4d81d245dc98b3a26e8b2cfe68
3 N1ac2051dbd4849b0a68970de194e3081
4 N1e01e03d310c46fe8519a399feccd622
5 N22d5da831b374e1ba401ea8f0b29f05f
6 N39d0569596b84223a7047c38b569497f
7 N3fb24699995645fa84b7d7fe612331fc
8 N43c6874da9b64463a5369e669d38b869
9 N4525d5e3d18246cb8f1a9a20d85edc49
10 Na592a9c1c0c8456785f3cfed38f3237f
11 Nac25fe7c4947440c961e9633c7079ee0
12 Nc3138ea4b0e9436ca0580b072fa7b232
13 Nc888ed26532540ad9a1b23de12518e03
14 Ncadc37f75e8f49e2bb04d7332077d18d
15 Ncea3fcc4285949418f99d5e41f46cc02
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author N05e4cb08dff64d52ba21ca75e42adc2b
19 schema:citation sg:pub.10.1038/onc.2010.545
20 sg:pub.10.1186/2193-1801-3-710
21 https://doi.org/10.1001/jamaoncol.2016.2453
22 https://doi.org/10.1001/jamaoncol.2017.2925
23 https://doi.org/10.1002/cam4.348
24 https://doi.org/10.1002/cncr.29812
25 https://doi.org/10.1016/j.canep.2015.10.003
26 https://doi.org/10.1016/j.chest.2017.04.177
27 https://doi.org/10.1016/j.cllc.2017.02.001
28 https://doi.org/10.1016/j.ejca.2008.10.026
29 https://doi.org/10.1016/j.ijrobp.2017.01.178
30 https://doi.org/10.1016/j.jtho.2017.09.945
31 https://doi.org/10.1016/j.lungcan.2013.05.011
32 https://doi.org/10.1016/j.lungcan.2017.11.019
33 https://doi.org/10.1016/s1470-2045(17)30074-8
34 https://doi.org/10.1056/nejmc1514790
35 https://doi.org/10.1056/nejmoa1504627
36 https://doi.org/10.1056/nejmoa1507643
37 https://doi.org/10.1056/nejmoa1613493
38 https://doi.org/10.1056/nejmoa1801946
39 https://doi.org/10.1093/annonc/mds023
40 https://doi.org/10.1097/jto.0000000000000687
41 https://doi.org/10.1097/jto.0b013e3182762ce4
42 https://doi.org/10.1136/esmoopen-2017-000236
43 https://doi.org/10.1158/1078-0432.ccr-17-0527
44 https://doi.org/10.1177/1758835918763493
45 https://doi.org/10.1634/theoncologist.2015-0507
46 https://doi.org/10.1634/theoncologist.2016-0419
47 https://doi.org/10.1634/theoncologist.2017-0133
48 https://doi.org/10.21037/tlcr.2017.12.10
49 https://doi.org/10.21873/anticanres.12466
50 https://doi.org/10.3322/ca.2007.0011
51 https://doi.org/10.3322/caac.21340
52 https://doi.org/10.3322/caac.21387
53 schema:datePublished 2018-07
54 schema:datePublishedReg 2018-07-01
55 schema:description African Americans (AA) have the highest incidence and mortality rates with lung cancer. They are diagnosed at an earlier age with more advanced disease. Programmed cell death protein-1 inhibitor, Nivolumab, was approved as a second-line agent after failure of platinum-based therapy for advanced or metastatic non-small cell lung cancer (NSCLC). The original studies leading to the approval of Nivolumab had insufficient AA patients, thus there is still inadequate knowledge on treatment outcomes among AA patients. Our primary study endpoints were to determine the median overall survival, 1-year overall survival rate, median progression-free survival, and 1-year progression-free survival rate of patients with advanced or metastatic non-small cell lung cancer on Nivolumab. Our secondary study endpoints were to determine the overall tumor response rate, median time to response, median duration of response, and incidence of treatment-related adverse events of grade 3 or 4. In this retrospective study, we reviewed the charts of 38 patients, 29 of which were AA, with advanced or metastatic NSCLC who received Nivolumab from March 1, 2015 until November 30, 2017 from a single community-based cancer center and compared our results with historical data. Adenocarcinoma was the most common histology (71%) among all patients. Seven (18%) continued to use Nivolumab while 21 (55%) discontinued the treatment mainly due to progression of the disease. The median overall survival was 21.4 months (95% CI 13.5-27.4) and 17.6 months (95% CI 11.5-27.6) for all the patients and AA, respectively. Both have statistically significant difference (P < 0.001) compared to the historical studies of Borghaei et al. and Brahmer et al. At 1 year, the overall survival rate was 73% (95% CI 50-86) and 66% (95% CI 40-82) for all patients and AA, respectively. The median progression-free survival was also statistically significant (P < 0.001) between all the patients 6.3 months (95% CI 2.8-8), AA 6.0 months (95% CI 2.3-8.0), and the said historical studies. The 1-year progression-free survival rate was 23% (95% CI 10-39) and 28% (95% CI 12-47) for all patients and AA, respectively. Overall tumor response rate which includes complete and partial responses was 21% (95% CI 10-37) and 24% (95% CI 10-43) for all patients and AA, respectively. The median time to response was 3 and 2.8 months for all patients and AA, respectively. The median duration of response was 3.8 and 4.0 months for all patients and AA, respectively. Treatment-related adverse events of grade 3 or 4 were reported in 8 and 10% in all patients and AA, respectively, similar to the rates previously shown. AA patients with advanced or metastatic NSCLC on Nivolumab had increased overall survival and progression-free survival with similar grade 3 or 4 treatment-related adverse events. Providing adequate access to immunotherapy is indispensable to maximize survival benefit for AA patients.
56 schema:genre research_article
57 schema:inLanguage en
58 schema:isAccessibleForFree false
59 schema:isPartOf N53dfb1427073412082f87b65ecf00e15
60 Nbac6df63f5c14fd6819b6782a3e45da8
61 sg:journal.1094524
62 schema:name Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center
63 schema:pagination 109
64 schema:productId N0bf6b992999c4713908c76789fa30647
65 N869b77daba3a434ca07cc21863d59d0d
66 Nb7b512ca45834e1289db8a8e0220261d
67 Ndfc3193a5bea44599d2840ff5e51f795
68 Ne010444d965c43c0b2fb15af3e89e34a
69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104908927
70 https://doi.org/10.1007/s12032-018-1171-y
71 schema:sdDatePublished 2019-04-10T20:05
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher N3572e546e0cb4a25a08b1fcf99668a6f
74 schema:url https://link.springer.com/10.1007%2Fs12032-018-1171-y
75 sgo:license sg:explorer/license/
76 sgo:sdDataset articles
77 rdf:type schema:ScholarlyArticle
78 N05e4cb08dff64d52ba21ca75e42adc2b rdf:first sg:person.016702546124.37
79 rdf:rest Nbc511b09f7d74c5f921abe209552713e
80 N064a95a29fc442b0888e2b47df827d91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Female
82 rdf:type schema:DefinedTerm
83 N0a1e0b4d81d245dc98b3a26e8b2cfe68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Middle Aged
85 rdf:type schema:DefinedTerm
86 N0bf6b992999c4713908c76789fa30647 schema:name dimensions_id
87 schema:value pub.1104908927
88 rdf:type schema:PropertyValue
89 N1ac2051dbd4849b0a68970de194e3081 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Aged
91 rdf:type schema:DefinedTerm
92 N1be3e6ea30044c23845489fb607ae337 rdf:first sg:person.01362157656.80
93 rdf:rest N5b40644dc84b41f6b3c18ab6ddc4dec1
94 N1e01e03d310c46fe8519a399feccd622 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Disease-Free Survival
96 rdf:type schema:DefinedTerm
97 N22d5da831b374e1ba401ea8f0b29f05f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Antibodies, Monoclonal
99 rdf:type schema:DefinedTerm
100 N3572e546e0cb4a25a08b1fcf99668a6f schema:name Springer Nature - SN SciGraph project
101 rdf:type schema:Organization
102 N39d0569596b84223a7047c38b569497f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Treatment Outcome
104 rdf:type schema:DefinedTerm
105 N3fb24699995645fa84b7d7fe612331fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name African Americans
107 rdf:type schema:DefinedTerm
108 N43c6874da9b64463a5369e669d38b869 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Male
110 rdf:type schema:DefinedTerm
111 N4525d5e3d18246cb8f1a9a20d85edc49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Carcinoma, Non-Small-Cell Lung
113 rdf:type schema:DefinedTerm
114 N53dfb1427073412082f87b65ecf00e15 schema:issueNumber 7
115 rdf:type schema:PublicationIssue
116 N5b40644dc84b41f6b3c18ab6ddc4dec1 rdf:first sg:person.0761661517.10
117 rdf:rest Ned5b3b3c44904247ac52526ae2bee21b
118 N869b77daba3a434ca07cc21863d59d0d schema:name readcube_id
119 schema:value e40e235f1b0f3597216ba58675df465f8e2bb9d294e117753c86ade66ba71f15
120 rdf:type schema:PropertyValue
121 Na592a9c1c0c8456785f3cfed38f3237f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Community Health Centers
123 rdf:type schema:DefinedTerm
124 Nac25fe7c4947440c961e9633c7079ee0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Follow-Up Studies
126 rdf:type schema:DefinedTerm
127 Nb7b512ca45834e1289db8a8e0220261d schema:name doi
128 schema:value 10.1007/s12032-018-1171-y
129 rdf:type schema:PropertyValue
130 Nbac6df63f5c14fd6819b6782a3e45da8 schema:volumeNumber 35
131 rdf:type schema:PublicationVolume
132 Nbc511b09f7d74c5f921abe209552713e rdf:first sg:person.010270370327.35
133 rdf:rest N1be3e6ea30044c23845489fb607ae337
134 Nc3138ea4b0e9436ca0580b072fa7b232 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Lung Neoplasms
136 rdf:type schema:DefinedTerm
137 Nc888ed26532540ad9a1b23de12518e03 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Antineoplastic Agents
139 rdf:type schema:DefinedTerm
140 Ncadc37f75e8f49e2bb04d7332077d18d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Retrospective Studies
142 rdf:type schema:DefinedTerm
143 Ncea3fcc4285949418f99d5e41f46cc02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 Ndfc3193a5bea44599d2840ff5e51f795 schema:name pubmed_id
147 schema:value 29915891
148 rdf:type schema:PropertyValue
149 Ne010444d965c43c0b2fb15af3e89e34a schema:name nlm_unique_id
150 schema:value 9435512
151 rdf:type schema:PropertyValue
152 Ned5b3b3c44904247ac52526ae2bee21b rdf:first sg:person.016130301335.85
153 rdf:rest rdf:nil
154 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
155 schema:name Medical and Health Sciences
156 rdf:type schema:DefinedTerm
157 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
158 schema:name Oncology and Carcinogenesis
159 rdf:type schema:DefinedTerm
160 sg:journal.1094524 schema:issn 1357-0560
161 1559-131X
162 schema:name Medical Oncology
163 rdf:type schema:Periodical
164 sg:person.010270370327.35 schema:affiliation https://www.grid.ac/institutes/grid.239276.b
165 schema:familyName Potdar
166 schema:givenName Rashmika
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010270370327.35
168 rdf:type schema:Person
169 sg:person.01362157656.80 schema:affiliation https://www.grid.ac/institutes/grid.239276.b
170 schema:familyName Djibo
171 schema:givenName Djeneba Audrey
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362157656.80
173 rdf:type schema:Person
174 sg:person.016130301335.85 schema:affiliation https://www.grid.ac/institutes/grid.239276.b
175 schema:familyName Dourado
176 schema:givenName Claudia
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016130301335.85
178 rdf:type schema:Person
179 sg:person.016702546124.37 schema:affiliation https://www.grid.ac/institutes/grid.239276.b
180 schema:familyName Tiu
181 schema:givenName Andrew C.
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016702546124.37
183 rdf:type schema:Person
184 sg:person.0761661517.10 schema:affiliation https://www.grid.ac/institutes/grid.239276.b
185 schema:familyName Masab
186 schema:givenName Muhammad
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761661517.10
188 rdf:type schema:Person
189 sg:pub.10.1038/onc.2010.545 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038051303
190 https://doi.org/10.1038/onc.2010.545
191 rdf:type schema:CreativeWork
192 sg:pub.10.1186/2193-1801-3-710 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023434538
193 https://doi.org/10.1186/2193-1801-3-710
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1001/jamaoncol.2016.2453 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004154633
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1001/jamaoncol.2017.2925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092066753
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1002/cam4.348 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045531700
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1002/cncr.29812 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046490428
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/j.canep.2015.10.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034640872
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/j.chest.2017.04.177 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085384884
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/j.cllc.2017.02.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083906247
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/j.ijrobp.2017.01.178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084739783
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/j.jtho.2017.09.945 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092571697
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1016/j.lungcan.2013.05.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013015846
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1016/j.lungcan.2017.11.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092855159
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1016/s1470-2045(17)30074-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084052467
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1056/nejmc1514790 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013879074
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1056/nejmoa1504627 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052572745
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1056/nejmoa1507643 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000663586
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1056/nejmoa1613493 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086112913
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1056/nejmoa1801946 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103285297
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1093/annonc/mds023 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031642811
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1097/jto.0000000000000687 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051740635
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1097/jto.0b013e3182762ce4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048177896
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1136/esmoopen-2017-000236 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091409434
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1158/1078-0432.ccr-17-0527 schema:sameAs https://app.dimensions.ai/details/publication/pub.1093088390
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1177/1758835918763493 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103149559
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1634/theoncologist.2015-0507 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026363244
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1634/theoncologist.2016-0419 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084355313
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1634/theoncologist.2017-0133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086386152
248 rdf:type schema:CreativeWork
249 https://doi.org/10.21037/tlcr.2017.12.10 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099894161
250 rdf:type schema:CreativeWork
251 https://doi.org/10.21873/anticanres.12466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101851958
252 rdf:type schema:CreativeWork
253 https://doi.org/10.3322/ca.2007.0011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050648457
254 rdf:type schema:CreativeWork
255 https://doi.org/10.3322/caac.21340 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002091226
256 rdf:type schema:CreativeWork
257 https://doi.org/10.3322/caac.21387 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014894112
258 rdf:type schema:CreativeWork
259 https://www.grid.ac/institutes/grid.239276.b schema:alternateName Albert Einstein Medical Center
260 schema:name Department of Medicine, Einstein Medical Center, 5501 Old York Road, 19141, Philadelphia, PA, USA
261 Division of Hematology and Medical Oncology, Einstein Medical Center, Philadelphia, PA, USA
262 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...